LLY vs. ALNY
LLY (Eli Lilly and Company) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — LLY in Drug Manufacturers - General, ALNY in Biotechnology. Over the past 10 years, LLY returned 33.71%/yr vs 16.55%/yr for ALNY. At a 0.29 correlation, their price movements are largely independent.
Performance
LLY vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LLY achieves a 7.29% return, which is significantly higher than ALNY's -26.53% return. Over the past 10 years, LLY has outperformed ALNY with an annualized return of 33.71%, while ALNY has yielded a comparatively lower 16.55% annualized return.
LLY
- 1D
- 1.57%
- 1M
- 21.37%
- YTD
- 7.29%
- 6M
- 15.58%
- 1Y
- 50.32%
- 3Y*
- 38.07%
- 5Y*
- 39.75%
- 10Y*
- 33.71%
ALNY
- 1D
- -3.59%
- 1M
- -0.98%
- YTD
- -26.53%
- 6M
- -32.06%
- 1Y
- -2.88%
- 3Y*
- 15.25%
- 5Y*
- 13.17%
- 10Y*
- 16.55%
LLY vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 7.29% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
ALNY Alnylam Pharmaceuticals, Inc. | -26.53% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between LLY and ALNY is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 2004 | 0.29 |
The correlation between LLY and ALNY shifts across timeframes, from 0.17 (1 year) to 0.29 (all time), reflecting how their relationship changes across market environments.
Fundamentals
LLY:
$1.03T
ALNY:
$40.38B
LLY:
$28.14
ALNY:
$4.26
LLY:
40.83
ALNY:
68.52
LLY:
14.28
ALNY:
9.23
LLY:
33.00
ALNY:
37.55
LLY:
$72.25B
ALNY:
$4.29B
LLY:
$59.75B
ALNY:
$2.51B
LLY:
$32.97B
ALNY:
$729.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LLY vs. ALNY — Risk / Return Rank
LLY
ALNY
LLY vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LLY | ALNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.41 | ||
| Sortino ratioReturn per unit of downside risk | +1.75 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.02 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 2.14 | -0.07 | +2.21 |
| Martin ratioReturn relative to average drawdown | 5.32 | -0.12 | +5.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LLY | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.33 | -0.08 | +1.41 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.23 | 0.27 | +0.96 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 1.12 | 0.31 | +0.81 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.58 | 0.32 | +0.26 |
Drawdowns
LLY vs. ALNY - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.24%, smaller than the maximum ALNY drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for LLY and ALNY.
Loading charts...
Drawdown Indicators
| LLY | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.24% | -83.58% | +15.34% |
Max Drawdown (1Y)Largest decline over 1 year | -23.64% | -42.01% | +18.37% |
Max Drawdown (3Y)Largest decline over 3 years | -34.48% | -42.01% | +7.53% |
Max Drawdown (5Y)Largest decline over 5 years | -34.48% | -42.46% | +7.98% |
Max Drawdown (10Y)Largest decline over 10 years | -34.48% | -59.95% | +25.47% |
Current DrawdownCurrent decline from peak | 0.00% | -40.52% | +40.52% |
Average DrawdownAverage peak-to-trough decline | -19.22% | -30.59% | +11.37% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.49% | 23.22% | -13.73% |
Volatility
LLY vs. ALNY - Volatility Comparison
Eli Lilly and Company (LLY) and Alnylam Pharmaceuticals, Inc. (ALNY) have volatilities of 9.55% and 9.94%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LLY | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.55% | 9.94% | -0.39% |
Volatility (6M)Calculated over the trailing 6-month period | 27.05% | 26.34% | +0.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.16% | 36.87% | +1.29% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.54% | 48.88% | -16.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.18% | 53.66% | -23.48% |
Dividends
LLY vs. ALNY - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.56%, while ALNY has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.56% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
LLY vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LLY vs. ALNY - Profitability Comparison
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.
Frequently Asked Questions
LLY and ALNY have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALNY has higher volatility (9.94%) compared to LLY (9.55%). In terms of maximum drawdown, LLY dropped -68.24% vs ALNY's -83.58%.
LLY currently has the higher Sharpe Ratio (1.33 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LLY and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer